CencoraRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Cencora (COR) reported revenue of $78.36B in Q1 2026, with Animal Health its largest revenue segment at 70%.
CencoraPharmaceutical distributor formerly AmerisourceBergen, renamed in 2023. FY2025 revenue rose 9.3% to $321.3B, growth the company attributes largely to higher-priced new therapies including the GLP-1 class; US Healthcare Solutions revenue specifically cites diabetes and weight-loss labelled products.
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Cencora (COR) is a Medical - Distribution company. Pharmaceutical distributor formerly AmerisourceBergen, renamed in 2023. FY2025 revenue rose 9.3% to $321.3B, growth the company attributes largely to higher-priced new therapies including the GLP-1 class; US Healthcare Solutions revenue specifically cites diabetes and weight-loss labelled products. It was founded in 2001, is headquartered in Conshohocken, PA and employs about 51,000 people.
As of 2026-Q1, Cencora's revenue breaks down across Animal Health (70%), Other Segments (30%). See the revenue-by-segment chart for the full mix.
Track Cencora's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups Cencora in the GLP-1 sector, alongside Hims & Hers Health (HIMS), McKesson (MCK), Cardinal Health (CAH) and CVS Health (CVS).
If you are researching Cencora, also look at Hims & Hers Health (HIMS), McKesson (MCK) and Cardinal Health (CAH). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.